Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Stanford, CA, USA.
Dig Dis Sci. 2020 Mar;65(3):897-905. doi: 10.1007/s10620-020-06100-0.
Chronic liver disease is a major cause of morbidity and mortality worldwide. Even though effective treatments are now available for most chronic viral hepatitis, treatment options for other causes of chronic liver disease remain inadequate. Recent research has revealed a previously unappreciated role that the human intestinal microbiome plays in mediating the development and progression of chronic liver diseases. The recent remarkable success of fecal microbiota transplantation (FMT) in treating Clostridioides difficile demonstrates that the intestinal microbiota can be manipulated to obtain favorable therapeutic benefits and that FMT may become an important component of a total therapeutic approach to effectively treat hepatic disorders.
慢性肝病是全球范围内发病率和死亡率的主要原因。尽管现在大多数慢性病毒性肝炎都有有效的治疗方法,但其他原因导致的慢性肝病的治疗选择仍然不足。最近的研究揭示了人类肠道微生物组在介导慢性肝病的发生和发展中以前未被认识到的作用。最近粪便微生物群移植(FMT)在治疗艰难梭菌中的显著成功表明,可以对肠道微生物群进行操纵以获得有利的治疗益处,并且 FMT 可能成为有效治疗肝障碍的综合治疗方法的重要组成部分。